PRNP E200K

What does it look like clinically?

A CJD phenotype, frequently indistinguishable from sporadic CJD at the bedside. The 2017 review gives literature onset averaging about 60 years with a range of 33 to 84, and a median duration of 5 to 10 months with a range of 1 to 18 months. In the UCSF centre’s own series it was the commonest variant, with 43 symptomatic cases across 31 families, onset from 36 to 84 years and one patient with a duration of 78 months.

That long outlier is important. The typical course is measured in months, and a minority of carriers have a course measured in years, so a slowly progressive illness in an E200K family is not evidence against the diagnosis.

Where is it common?

It is described as the most common mutation worldwide, and it is concentrated in particular populations through founder effects. The 2026 Israeli practice framework states that genetic CJD is relatively common in Israel because of the E200K founder variant, found mainly in people of Libyan and Tunisian Jewish descent, and reports that requests for presymptomatic testing have risen since 2018.

That clustering is why Israel produced the first consensus framework written specifically for relatives of people with CJD, and why much of the presymptomatic research in genetic prion disease is E200K-based.

Why do so many patients have no family history?

Because penetrance is incomplete and age-dependent, and because family histories are imperfect. The 2017 review states that penetrance is high but that about half of patients have no family history.

A 2022 review lists the usual explanations for an absent history: low penetrance, misdiagnosis in earlier generations, death from other causes before onset, misattributed parentage and incomplete family knowledge. With onset averaging around 60, a carrier who dies of something else in their fifties leaves no trace in the pedigree.

The consequence for practice is that a PRNP test in a patient with suspected CJD is not reserved for those with a family history, and that relatives should not be reassured on the basis of one.

What are the penetrance estimates?

E200K is in the high-penetrance group, with the most quantified uncertainty of the four.

The 2016 population-control analysis compared 16,025 prion disease cases against 60,706 ExAC exomes and 531,575 genotyped individuals. Allele frequencies for E200K, D178N, P102L and A117V were consistent with up to 100 percent penetrance, and for E200K the authors noted that the interval includes survival-analysis estimates in the region of 60 to 90 percent. A 2022 review describes E200K as exhibiting incomplete and age-associated penetrance, with most carriers developing illness as they age, and notes that an international study of carriers did not confirm earlier reports of anticipation, attributing those to ascertainment bias.

Anticipation, the idea that onset gets earlier in successive generations, comes up often in E200K families because it appears to be visible in a pedigree. It is worth addressing directly: the published analysis did not support it.

Does the transmission figure differ from 50 percent?

Possibly, and E200K is where the largest departure was reported. The 2025 study of 24 pedigrees, 65 nuclear families and 151 offspring reported 70.5 percent transmission for E200K, with a 95 percent confidence interval of 60.4 to 80.6. Maternal transmission was 67.3 percent and paternal 78.3 percent, the strongest paternal bias in the study; the authors wrote that the mechanisms behind the paternal bias require further investigation.

The same caveats apply as elsewhere: retrospective design, 18 percent of genotypes inferred, specialised referral sources, and an explicit call for prospective validation before counselling protocols change. The figure in current guidance remains 50 percent per child.

How do the diagnostic tests behave?

Better than in the other inherited forms, which is worth knowing because it means a negative result carries more weight here than in FFI or GSS.

In the 2026 Canadian comparison of 116 diagnostic CSF samples, all 7 E200K cases were detected by all three assays: the modified deer mouse end-point assay, the standard hamster end-point assay and second-generation IQ-CSF RT-QuIC. By contrast the FFI D178N cases were missed entirely by IQ-CSF.

E200K also appears in work on substrate choice: a January 2026 report from a German group describes an E200K substrate raising CSF sensitivity in sporadic CJD and in fatal familial insomnia. That work is reported from conference abstract figures rather than a full paper read for this page, so it is flagged here as a development rather than quoted. How prion disease is diagnosed covers the panel.

What does counselling look like in E200K families?

The 2026 Israeli framework is the most specific published source, written by a 23-member multidisciplinary panel from six centres with a family representative reviewing the draft, and finalised in July 2025.

Its sequence is counselling, psychological assessment, blood sampling, then disclosure in person by the same clinician who gave the counselling, with at least a month between counselling and sampling and expedited timing permitted in special cases such as pregnancy. Testing is not offered under 18, and young adults roughly 18 to 25 receive careful review of motivation, emotional resilience and impulsivity. People in acute distress, such as after a relative’s diagnosis or death, are encouraged to delay at least six months. Testing is usually by targeted Sanger sequencing for E200K in a certified laboratory, with results going only to the referring team. The panel recommends public funding of counselling and testing, and notes that Israel lacks a structured support programme for carriers, calling for one to be developed.

Genetic counselling comes first and predictive testing: more detail set this out in general terms. Declining a test remains a recognised choice.

What research is open to carriers?

E200K carriers are the population most of the presymptomatic work recruits. A natural history study at Tel Aviv Sourasky Medical Center follows first-degree relatives of E200K patients aged 50 or over, enrolling both carriers and non-carriers, with a planned 106 healthy relatives split evenly, about four years of follow-up and assessments every six months including MRI, lumbar puncture and polysomnography. It assumed a 13.6 percent phenoconversion rate among carriers over four years for its sample size calculation, which is a planning assumption rather than a published risk estimate.

Joining research without learning your status: more detail covers which studies require a known genotype, and current trials records sponsor-stated eligibility with dates.

Where next?

PRNP variants is the overview, D178N the variant where codon 129 decides the syndrome, M232R the low-risk end of the range, and E200K for researchers the scientific page.

This page summarises published literature and is not clinical or genetic advice. No figure here describes the position of any particular person, and nothing here is a reason to have, or not to have, a test.